BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems

"BioVaxys is at the forefront of a significant shift in the drug delivery landscape," James Passin, CEO of BioVaxys, stated, "These groundbreaking study results validate our strategic position in an important segment of the multi-billion drug delivery market. DPX not only outperforms current antigen delivery solutions but also demonstrate ...read more